Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

DCM-NEXT

Financiado

Enabling advances in diagnosis, patient stratification and treatment for dilated...

Enabling advances in diagnosis, patient stratification and treatment for dilated cardiomyopathy patients and families. Dilated Cardiomyopathy (DCM) is a heart muscle disorder characterised by thinning and stretching of the heart ventricles, making it harder for the heart to pump blood (systolic dysfunction). This disorder, with an estimated preval... ver más

30/09/2027

STICHTING AMSTERDA...

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

STICHTING AMSTERDAM UMC No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 8 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-06-20

HORIZON-EIC-2022-PATHFINDERCHALLENGES-01-03: EIC Pathfinder Challenge: Cardiogen... Scope:Cardiogenomics holds the potential to address existing gaps in the diagnosis and treatment of...

I+D

Cerrada hace 2 años

0% 100% 100%

8 Participantes

STICHTING AMSTERDAM UMC

2.03M€ | Lider

IMPERIAL COLLEGE OF SCIENCE...

N.D. | Participante

FONDATION CARDIOMETABOLISME...

324.78K€ | Participante

MDC

576.88K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2021-128698OB-I00 ESTUDIO AVANZADO DEL NICHO CARDIOVASCULAR ASOCIADO A LA POBL... 169K€ Cerrado

PID2019-110155RA-I00 REGULACION TRANSCRIPCIONAL Y SEÑALIZACION CELULAR EN LA DIFE... 109K€ Cerrado

PTQ-11-05005 Optimización de un método de diagnóstico de riesgo genético,... 64K€ Cerrado

BIO2011-25369 BUSQUEDA RAPIDA Y RENTABLE DE CARDIOMIOPATIAS MEDIANTE ANALI... 145K€ Cerrado

FJC2020-042788-I Espectro genético de la miocardiopatía dilatada 53K€ Cerrado

PLEC2022-009235 Mecanometabolismo de la insuficiencia cardiaca asociada a la... 563K€ Cerrado

Duración del proyecto: 51 meses Fecha Inicio: 2023-06-20
Fecha Fin: 2027-09-30

Líder del proyecto

STICHTING AMSTERDAM UMC No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Descripción del proyecto Dilated Cardiomyopathy (DCM) is a heart muscle disorder characterised by thinning and stretching of the heart ventricles, making it harder for the heart to pump blood (systolic dysfunction). This disorder, with an estimated prevalence of up to 1/250, predominantly affects younger adults. It is associated with significant morbidity and mortality, including heart failure and sudden cardiac death, with end-stage DCM being the leading indication for heart transplantation. The current disease burden in DCM is largely attributable to two important gaps in scientific knowledge: Firstly, our understanding of the aetiology and genetic architecture of DCM remains limited, hindering the utility of genetic testing in clinical patient management. Secondly, there are limited therapeutic options for DCM patients. Existing therapies are generic and target symptoms. No curative treatments exist, apart from invasive heart transplantation and there are no approved therapies targeting underlying molecular disease mechanisms. A fuller understanding of the genetic architecture of DCM and knowledge of the genes and genetic variants involved are critically needed to provide solutions for these unmet medical needs. The DCM-NEXT consortium combines world-leading interdisciplinary expertise and resources of 8 investigators in the fields of DCM, deep clinical phenotyping, cardiogenomics, cardiac transcriptomics, artificial intelligence, in silico drug target discovery and functional studies. They will uniquely leverage their unparalleled cohort of 11,750 DCM probands and relatives with extensive clinical and omics data. Through cutting-edge genomic and cardiac transcriptomic studies, the project aims to (1) revolutionise genetic testing and patient stratification for more precise prediction of disease onset, progression and risk of major adverse cardiac events; and (2) accelerate development of novel therapies by identifying and validating targets involved in pathogenesis of DCM.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores